Cargando…

Impact of Anti-Tuberculosis Drug Use on Treatment Outcomes in Patients with Pulmonary Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: A Nationwide Retrospective Cohort Study with Propensity Score Matching

BACKGROUND: Effective treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis (FQr-MDR-TB) is difficult because of the limited number of available core anti-TB drugs and high rates of resistance to anti-TB drugs other than FQs. However, few studies have examined anti-TB drugs that ar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Hongjo, Jeong, Dawoon, Kang, Young Ae, Jeon, Doosoo, Kang, Hee-Yeon, Kim, Hee Jin, Kim, Hee-Sun, Mok, Jeongha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Tuberculosis and Respiratory Diseases 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323203/ https://www.ncbi.nlm.nih.gov/pubmed/37254489 http://dx.doi.org/10.4046/trd.2023.0040

Ejemplares similares

Nationwide Treatment Outcomes of Patients With Multidrug/Rifampin-Resistant Tuberculosis in Korea, 2011–2017: A Retrospective Cohort Study (Korean TB-POST)
por: Choi, Hongjo, et al.
Publicado: (2023)

Retreatment after loss to follow-up reduces mortality in patients with multidrug/rifampicin-resistant tuberculosis
por: Choi, Hongjo, et al.
Publicado: (2023)

Prevalence and associated factors of diabetes mellitus among patients with tuberculosis in South Korea from 2011 to 2018: a nationwide cohort study
por: Jeong, Dawoon, et al.
Publicado: (2023)

Additional Drug Resistance in Patients with Multidrug-resistant Tuberculosis in Korea: a Multicenter Study from 2010 to 2019
por: Lee, Taehoon, et al.
Publicado: (2021)

Trend of multidrug and fluoroquinolone resistance in Mycobacterium tuberculosis isolates from 2010 to 2014 in Korea: a multicenter study
por: Kim, Hyeonseok, et al.
Publicado: (2019)

Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Concern to Bedaquiline: Authors’ Reply
por: Kang, Yewon, et al.
Publicado: (2022)

Risk factors associated with tuberculosis recurrence in South Korea determined using a nationwide cohort study
por: Youn, Hin Moi, et al.
Publicado: (2022)

Cohort Profile: Korean Tuberculosis and Post-Tuberculosis Cohort Constructed by Linking the Korean National Tuberculosis Surveillance System and National Health Information Database
por: Jeong, Dawoon, et al.
Publicado: (2022)

Real-world impact of the fixed-dose combination on improving treatment outcomes of drug-susceptible tuberculosis: a comparative study using multiyear national tuberculosis patient data
por: Ki, Min Seo, et al.
Publicado: (2023)

Fluoroquinolone resistance in multidrug-resistant tuberculosis patients
por: Lee, Hyun-Woo, et al.
Publicado: (2019)

Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design
por: Mok, Jeong Ha, et al.
Publicado: (2017)

Resistance patterns, prevalence, and predictors of fluoroquinolones resistance in multidrug resistant tuberculosis patients
por: Ahmad, Nafees, et al.
Publicado: (2015)

Impact of Molecular Drug Susceptibility Testing on the Time to Multidrug-resistant Tuberculosis Treatment Initiation
por: Jeon, Doosoo, et al.
Publicado: (2020)

Improved Fluoroquinolone-Resistant and Extensively Drug-Resistant Tuberculosis Treatment Outcomes
por: Lee, Eun Hye, et al.
Publicado: (2019)

Medical Management of Drug-Resistant Tuberculosis
por: Jeon, Doosoo
Publicado: (2015)

Heterogeneous effects of COVID-19 control measures on tuberculosis in South Korea: an analysis of case notification data
por: Kim, Honghyok, et al.
Publicado: (2022)

Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Comparison of Pre- and Post-Public–Private Mix Periods
por: Kang, Yewon, et al.
Publicado: (2021)

Gender differences in tuberculosis patients with comorbidity: A cross-sectional study using national surveillance data and national health insurance claims data in South Korea
por: Moon, Daseul, et al.
Publicado: (2023)

Linezolid-induced black hairy tongue in a patient with multidrug-resistant tuberculosis: A case report
por: Lee, Jaemin, et al.
Publicado: (2021)

Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial
por: Lee, Myungsun, et al.
Publicado: (2019)

Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
por: Yang, Jeong Seong, et al.
Publicado: (2018)

Time to appropriate treatment in patients with multidrug-resistant tuberculosis in South Korea: Are we still in 2010?
por: Jo, Eun-Jung, et al.
Publicado: (2019)

Protocol of a Nationwide Observational Study among Patients with Nontuberculous Mycobacterium Pulmonary Disease in South Korea (NTM-KOREA)
por: Kwak, Nakwon, et al.
Publicado: (2020)

Proportion of Multidrug-Resistant Tuberculosis in Human Immunodeficiency Virus/Mycobacterium tuberculosis Co-Infected Patients in Korea
por: Joh, Joon Sung, et al.
Publicado: (2012)

WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea
por: Jeon, Doosoo
Publicado: (2017)

Case Report: Dynamics of Acquired Fluoroquinolone Resistance under Standardized Short-Course Treatment of Multidrug-Resistant Tuberculosis
por: Ngabonziza, Jean Claude Semuto, et al.
Publicado: (2020)

Characterization of Fluoroquinolone-Resistant and Multidrug-Resistant Mycobacterium tuberculosis Isolates Using Whole-Genome Sequencing in Tianjin, China
por: Wang, Zhirui, et al.
Publicado: (2022)

Targeting Multidrug Resistant Mycobacterium tuberculosis HtrA2 with Identical Chemical Entities of Fluoroquinolones
por: Daisy, P., et al.
Publicado: (2012)

High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region
por: Dreyer, Viola, et al.
Publicado: (2022)

Drug Resistance Patterns of Multidrug- and Extensively Drug-Resistant Tuberculosis in Korea: Amplification of Resistance to Oral Second-line Drugs
por: Kim, Chang-Ki, et al.
Publicado: (2017)

Multidrug-resistant tuberculosis
por: Zager, Ellen M, et al.
Publicado: (2008)

Multidrug-resistant tuberculosis
por: Lemos, Antônio Carlos Moreira, et al.
Publicado: (2013)

The burden and predictors of latent tuberculosis infection among immigrants in South Korea: a retrospective cross-sectional study
por: Yu, Sarah, et al.
Publicado: (2021)

Fluoroquinolone-Resistant Mycobacterium tuberculosis, Pakistan, 2005–2009
por: Jabeen, Kauser, et al.
Publicado: (2011)

Comparison of different regimens with or without fluoroquinolone in isoniazid-resistant tuberculosis: A multicenter cohort study
por: Min, Jinsoo, et al.
Publicado: (2022)

Multidrug-resistant tuberculosis/rifampicin-resistant tuberculosis: Principles of management
por: Prasad, Rajendra, et al.
Publicado: (2018)

Comparison of Disability-Adjusted Life Years (DALYs) and Economic Burden on People With Drug-Susceptible Tuberculosis and Multidrug-Resistant Tuberculosis in Korea
por: Lee, SeungCheor, et al.
Publicado: (2022)

Correlation of gyr Mutations with the Minimum Inhibitory Concentrations of Fluoroquinolones among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Bangladesh
por: Uddin, Mohammad Khaja Mafij, et al.
Publicado: (2021)

Effects of Bedaquiline Combined with Fluoroquinolone and/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: a Retrospective Study
por: Li, Rong, et al.
Publicado: (2023)

Additional Drug Resistance of Multidrug-Resistant Tuberculosis in Patients in 9 Countries
por: Kurbatova, Ekaterina V., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_mtfe1qk46snjnr6fudc2rvh1a9